Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in Acute Heart Failure Patients

Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in Acute Heart Failure Patients

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 22 Aug 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Serelaxin (Primary)
  • Indications Acute heart failure
  • Focus Registrational; Therapeutic Use
  • Acronyms Relax-AHF-2
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 22 Aug 2019 Primary endpoint (Percentage of Participants With Worsening of Heart Failure (WHF) Through Day 5) has not been met, according to the results published in the New England Journal of Medicine
    • 22 Aug 2019 Primary endpoint (Percentage of Participants With Confirmed Cardiovascular (CV) Death Through Day 180) has not been met, according to the results published in the New England Journal of Medicine
    • 22 Aug 2019 Results published in the New England Journal of Medicine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top